The clinical potential of C-peptide replacement in type 1 diabetes.
about
Diabetic complications within the context of aging: Nicotinamide adenine dinucleotide redox, insulin C-peptide, sirtuin 1-liver kinase B1-adenosine monophosphate-activated protein kinase positive feedback and forkhead box O3Physiological effects and therapeutic potential of proinsulin C-peptideThe Physiology of Proinsulin C-Peptide: Unanswered Questions and a Proposed ModelC-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-AnalysisClinical utility of insulin and insulin analogs.C-peptide and diabetic kidney disease.The role of insulin C-peptide in the coevolution analyses of the insulin signaling pathway: a hint for its functions.Influence of food patterns on endothelial biomarkers: a systematic review.Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice.Lack of associations between betatrophin/ANGPTL8 level and C-peptide in type 2 diabetic subjects.Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes modelThe clinical utility of C-peptide measurement in the care of patients with diabetesC-peptide activates AMPKα and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes.Synergistic effects of C-peptide and insulin on low O2-induced ATP release from human erythrocytes.C-peptide exhibits a late induction effect on matrix metallopeptidase-9 in high glucose-stimulated rat mesangial cells.Insulin gene therapy from design to beta cell generation.Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?Residual C-peptide in type 1 diabetes: what do we really know?Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure.C-peptide antioxidant adaptive pathways in β cells and diabetes.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.C-peptide and zinc delivery to erythrocytes requires the presence of albumin: implications in diabetes explored with a 3D-printed fluidic device.Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic β-cell function and insulin secretion.Autocrine C-peptide mechanism underlying INS1 beta cell adaptation to oxidative stress.Enhanced insulin action following subcutaneous co-administration of insulin and C-peptide in rats.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Efficacy of a long-acting C-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice.Effect of C-peptide Alone or in Combination with Nicotinamide on Insulin Levels from Pancreatic Islets in Mouse.Prevention of VEGF-mediated microvascular permeability by C-peptide in diabetic mice.Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis.C-peptide and the pathophysiology of microvascular complications of diabetes.Impact of novel N-aryl piperamide NO donors on NF-κB translocation in neuroinflammation: rational drug-designing synthesis and biological evaluation.Association between low C-peptide and fragility fractures in postmenopausal women without diabetes.
P2860
Q26749486-6AB7D72B-84B2-446F-A652-7F133FF4FF3CQ27012286-60AEB59E-204B-42F0-8CBE-E803A4FAC7CDQ27015746-D1BC7249-2A51-4594-ABF5-5BCCE58C987AQ27306601-B3A49928-EA61-4178-881E-2A0C7BE96479Q30429358-94983E81-9759-4275-B0EE-C77BAA559DA9Q34540591-E5986FDA-D7C2-4FB9-8B5A-9587648C6A59Q34541299-C22F1823-DAA6-4ACD-A85C-8084DCF354FDQ34735012-9ABAA72D-E05F-42E2-9391-4C1A3091DAD8Q35564499-AEB74A44-19F5-40B3-82EF-B68D3FF1AC7AQ35986455-10B34DF0-31E8-434B-8A08-A6604EED58C9Q36535440-0A4E9EE6-68AE-4586-BC1B-4429341BB713Q37108880-E8638522-C152-49B8-B91F-27BAD5852E58Q37251110-C15509A2-66D7-4CAE-90EC-8CAB07B225F2Q37440642-D1A126AF-F339-498B-BBC6-128B0E45A847Q37581535-C6772816-25F7-4E86-A579-44C1EE506E88Q38051768-CA6B9EEB-7F8E-4EAE-BBF2-BC0693E60D8FQ38086802-246DCF00-F181-479C-A6DB-334A4A87B4BAQ38197230-EF9E3843-4DF4-494F-8E5C-76C216C6C90EQ38692770-26F5AE10-5029-44B8-A68A-40E810F9B2E2Q38850708-729873B4-218C-4060-8FD3-33F0133FB899Q38866310-997BD83B-17D7-40B6-9691-46ED51150E61Q38892829-646B3FF3-CC89-448A-A971-70EFF7E54BBDQ39007804-46B94FD2-BEBE-4BFA-A967-33854E128F88Q39031176-5C50B772-1DD2-4E39-8BC3-487E014E9C5FQ39096910-E4926875-E6A4-4905-B0FD-2B6D5BDA185AQ39112475-18330509-2C26-4480-AD56-4058599F06B0Q41026519-7A5D3CC3-D4FD-4C0F-AE35-AD1D3E320DC4Q41898092-7D3ADE47-42B6-4450-8DD0-D65DA2B6D744Q45993671-AFE20904-ABF7-4ABC-AD03-15577650322BQ46248035-03E83707-47CD-4CA9-9C3E-9CA84FEE7C5EQ46443007-0C21619A-D1D5-497B-9E2B-9F1496218B1EQ49959079-41465EFD-12E7-4722-8EF0-6A1C131C3857Q51829054-670CF230-D589-493A-A07B-95C4682C28AF
P2860
The clinical potential of C-peptide replacement in type 1 diabetes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The clinical potential of C-peptide replacement in type 1 diabetes.
@ast
The clinical potential of C-peptide replacement in type 1 diabetes.
@en
type
label
The clinical potential of C-peptide replacement in type 1 diabetes.
@ast
The clinical potential of C-peptide replacement in type 1 diabetes.
@en
prefLabel
The clinical potential of C-peptide replacement in type 1 diabetes.
@ast
The clinical potential of C-peptide replacement in type 1 diabetes.
@en
P2860
P921
P356
P1433
P1476
The clinical potential of C-peptide replacement in type 1 diabetes.
@en
P2093
Anders A F Sima
Asa Kallas
P2860
P304
P356
10.2337/DB11-1423
P407
P50
P5008
P577
2012-04-01T00:00:00Z